n new cancer patients in China annually. The overall size of the anti-tumor drug market is nearly 100 billion yuan, but this is far from meeting the actual needs.
It is true that the development of China's anti-tumor drug market is lagging behind, and also deformed. A large number of cancer-assisted drugs and proprietary Chinese medicine wasted health insurance resources. Thus those drugs which really have the exact effect discourage many patients due to tender, or because of health insurance adjustment and other reasons.
With the development of gene detection technology, precision medicine has arrived. In the field of anti-tumor, gene-based targeting drugs have become first-line anti-tumor drugs, because the targeted drug effect is significant with light side effects.
But we should see that the tumor gene is complex, and the existing drug coverage target is small. Also, targeted drugs’ resistance, blindly following of the trend, imitation of many enterprises become a limiting factor in the development of targeted drugs. Data show that the treatment of lung cancer gefitinib, for example, CFDA in the approval of the business as many as 40, erlotinib is up to more than 100. Does this mean that the target drug is poor? Of course not, the future of targeted drugs must be one of the main anti-tumor drugs, like the field of antibiotics as blossom. For different targets have different drugs, we just pay attention not to go past the imitation of the old road. It is noteworthy that the development of anti-tumor drugs can not be completed overnight, as there is accumulation to continue.
Whether anti-tumor drugs can enter the health insurance is not only related to the health of millions of patients, but also related to the success or failure of a product. In the past, China's health insurance system has lagged behind, many cutting-edge, new listing of drugs can not be included in the medical insurance directory, which is also has a great relationship of the lag of enterprise education.
In this regard, domestic enterprises should fully learn some of the advanced experience of foreign companies. Some foreign tumor drug production enterprises will publish their progress of the process from time to time. once the clinical trial is successful, they can be quickly accepted by clinical and patient.